EA200901646A1 - Ингибиторы рецепторных тирозинкиназ и их применение - Google Patents

Ингибиторы рецепторных тирозинкиназ и их применение

Info

Publication number
EA200901646A1
EA200901646A1 EA200901646A EA200901646A EA200901646A1 EA 200901646 A1 EA200901646 A1 EA 200901646A1 EA 200901646 A EA200901646 A EA 200901646A EA 200901646 A EA200901646 A EA 200901646A EA 200901646 A1 EA200901646 A1 EA 200901646A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptor
tyrosine kinase
thyrozinkinase
inhibitors
receptor tyrosine
Prior art date
Application number
EA200901646A
Other languages
English (en)
Russian (ru)
Inventor
Джозеф Шлессингер
Ирит Лэкс
Сатору Юзава
Ярден Опатоуски
Ян Янг
Original Assignee
Йел Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Йел Юниверсити filed Critical Йел Юниверсити
Publication of EA200901646A1 publication Critical patent/EA200901646A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EA200901646A 2007-06-05 2008-06-05 Ингибиторы рецепторных тирозинкиназ и их применение EA200901646A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93323807P 2007-06-05 2007-06-05
US948207P 2007-12-28 2007-12-28
US7050608P 2008-03-24 2008-03-24
PCT/US2008/007104 WO2008153926A2 (en) 2007-06-05 2008-06-05 Inhibitors of receptor tyrosine kinases and methods of use thereof

Publications (1)

Publication Number Publication Date
EA200901646A1 true EA200901646A1 (ru) 2010-08-30

Family

ID=40130400

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200901646A EA200901646A1 (ru) 2007-06-05 2008-06-05 Ингибиторы рецепторных тирозинкиназ и их применение

Country Status (11)

Country Link
US (1) US9273134B2 (https=)
EP (1) EP2155238B1 (https=)
JP (2) JP2010529127A (https=)
CN (2) CN103694351A (https=)
AU (1) AU2008262384B9 (https=)
BR (1) BRPI0812400A2 (https=)
CA (1) CA2687896A1 (https=)
EA (1) EA200901646A1 (https=)
IL (1) IL202215A0 (https=)
MX (1) MX2009013269A (https=)
WO (1) WO2008153926A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2687896A1 (en) 2007-06-05 2008-12-18 Yale University Antibody directed against the d4 ig-like domain of the kit receptor
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
KR20120115348A (ko) * 2009-12-29 2012-10-17 예일 유니버시티 혈관 내피 성장 인자 (ｖｅｇｆ) 수용체의 억제제 및 그의 사용 방법
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
WO2011119948A1 (en) * 2010-03-26 2011-09-29 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP2656079A2 (en) * 2010-12-20 2013-10-30 Universiteit Gent Crystal structure of flt3 ligand-receptor complex
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
FR2970968A1 (fr) * 2011-02-01 2012-08-03 Isp Investments Inc Nouveaux peptides intervenant dans la voie de signalisation scf c-kit et compositions les comprenant
US9364414B2 (en) 2011-02-01 2016-06-14 Isp Investments Inc. Method to protect skin from ultraviolet radiation using novel peptides involved in the improvement of microparasol organization in keratinocytes
AR086044A1 (es) 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
ES2701051T3 (es) * 2013-03-15 2019-02-20 Novartis Ag Conjugados de anticuerpo-fármaco
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
JP6441949B6 (ja) * 2013-11-05 2019-01-30 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ヒト中和抗ｋｉｔ抗体及びその使用
WO2015109898A1 (zh) * 2014-01-24 2015-07-30 上海恒瑞医药有限公司 VEGF与PDGFRβ双特异性融合蛋白及其用途
CN113975386A (zh) 2014-05-23 2022-01-28 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
CN110072553B (zh) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
CN110818794B (zh) * 2019-11-27 2021-08-31 河南赛诺特生物技术有限公司 一种用于检测人cd117蛋白的单克隆抗体、偶联蛋白、抗原表位肽以及杂交瘤细胞株
WO2024155689A1 (en) * 2023-01-17 2024-07-25 Yale University Compounds and methods for inhibiting type-iii receptor tyrosine kinases
KR20250167153A (ko) 2023-03-03 2025-11-28 셀덱스 쎄라퓨틱스, 인크. 항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
WO2026002137A1 (zh) * 2024-06-27 2026-01-02 苏州必扬医药科技有限公司 一种蛋白酪氨酸激酶抑制剂游离碱的晶型
WO2026062524A1 (en) * 2024-09-17 2026-03-26 Otsuka Pharmaceutical Co., Ltd. Colony stimulating factor 1 receptor antibodies and methods of use thereof

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2543215A (en) 1947-06-03 1951-02-27 Wisconsin Alumni Res Found Process of preparing antibody-rich globulin fractions
US2520076A (en) 1947-07-18 1950-08-22 John W Williams Process for separating and recovering globulins from blood plasmas
US3597409A (en) 1970-05-25 1971-08-03 American Cyanamid Co Process for recoverring immunoglobulin a and immunoglobulin m
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4719290A (en) 1983-09-02 1988-01-12 Armour Pharmaceutical Corporation Composition of intravenous immune globulin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5268358A (en) 1988-12-08 1993-12-07 Cor Therapeutics, Inc. PDGF receptor blocking peptides
US5196524A (en) 1989-01-06 1993-03-23 Eli Lilly And Company Fusion reporter gene for bacterial luciferase
US7144731B2 (en) * 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5219737A (en) 1990-03-27 1993-06-15 Kikkoman Corporation Mutant luciferase of a firefly, mutant luciferase genes, recombinant dnas containing the genes and a method of producing mutant luciferase
US5712375A (en) 1990-06-11 1998-01-27 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6261774B1 (en) 1990-06-11 2001-07-17 Gilead Sciences, Inc. Truncation selex method
US5789157A (en) 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5763566A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US5864026A (en) 1990-06-11 1999-01-26 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DK0584082T3 (da) 1991-01-31 2000-10-16 Univ California Domæner i den ekstracellulære region af humane blodpladeafledte vækstfaktorreceptorpolypeptider
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
DE4205148A1 (de) 1991-05-25 1993-01-21 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen c-kit
US5229285A (en) 1991-06-27 1993-07-20 Kikkoman Corporation Thermostable luciferase of firefly, thermostable luciferase gene of firefly, novel recombinant dna, and process for the preparation of thermostable luciferase of firefly
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
NZ246242A (en) * 1991-12-02 1996-01-26 Cor Therapeutics Inc Inhibiting immunoglobulins acting on beta-platelet derived growth factor (pdgf)
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
EP0548867A2 (en) 1991-12-23 1993-06-30 Yeda Research And Development Co. Ltd. Soluble stem cell factor (SFC)-receptor
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
US6448077B1 (en) 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
JP3466765B2 (ja) 1994-07-27 2003-11-17 キッコーマン株式会社 ビオチン化ホタルルシフェラーゼ、ビオチン化ホタルルシフェラーゼ遺伝子、新規な組み換え体ｄｎａ、ビオチン化ホタルルシフェラーゼの製造法及び生物発光分析法
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
CA2219807C (en) 1995-05-03 2008-12-30 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6013443A (en) 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US6111095A (en) 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
US6936259B2 (en) * 1995-06-08 2005-08-30 University Of Saskatchewan CAMP factor of Streptococcus uberis
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5792613A (en) 1996-06-12 1998-08-11 The Curators Of The University Of Missouri Method for obtaining RNA aptamers based on shape selection
AU6763098A (en) 1997-03-19 1998-10-12 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
US5891646A (en) 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
DE19727814C1 (de) 1997-06-30 1998-10-01 Univ Eberhard Karls Anitkörper 4G8B4B12
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6689574B1 (en) 1997-10-07 2004-02-10 Merck & Co., Inc. Assays for nuclear receptor agonists and antagonists using fluorescence resonance energy transfer
AU3909199A (en) 1997-12-15 1999-07-05 Nexstar Pharmaceuticals, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US6458559B1 (en) 1998-04-22 2002-10-01 Cornell Research Foundation, Inc. Multivalent RNA aptamers and their expression in multicellular organisms
US6387620B1 (en) 1999-07-28 2002-05-14 Gilead Sciences, Inc. Transcription-free selex
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US20020048811A1 (en) 2000-10-16 2002-04-25 Devreotes Peter N. Receptor mediated activation of heterotrimeric G-proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20060223114A1 (en) 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20030082630A1 (en) 2001-04-26 2003-05-01 Maxygen, Inc. Combinatorial libraries of monomer domains
CA2450793A1 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
US7056685B1 (en) 2002-11-05 2006-06-06 Amgen Inc. Receptor ligands and methods of modulating receptors
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
EP1690097A2 (en) 2003-12-04 2006-08-16 Applied Research Systems ARS Holding N.V. Methods for identifying modulators of active kit tyrosine kinase receptor
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
US20060234299A1 (en) 2004-11-16 2006-10-19 Avidia Research Institute Protein scaffolds and uses thereof
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
WO2006094073A2 (en) 2005-03-02 2006-09-08 Acadia Pharmaceuticals Inc. Functional bioluminescence energy resonance transfer (bret) assay to screen, identify and characterize receptor tyrosine kinase ligands
WO2007004060A2 (en) * 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
JP2009509535A (ja) 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CA2687896A1 (en) 2007-06-05 2008-12-18 Yale University Antibody directed against the d4 ig-like domain of the kit receptor
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
KR20120115348A (ko) 2009-12-29 2012-10-17 예일 유니버시티 혈관 내피 성장 인자 (ｖｅｇｆ) 수용체의 억제제 및 그의 사용 방법
RU2012134637A (ru) 2010-01-14 2014-02-20 Йейл Юниверсити Ингибиторы рецепторных тирозинкиназ (rtk) и способы их применения
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
JP6776582B2 (ja) 2016-03-31 2020-10-28 Tdk株式会社 電子部品

Also Published As

Publication number Publication date
AU2008262384B2 (en) 2014-08-07
US20110311538A1 (en) 2011-12-22
MX2009013269A (es) 2010-04-21
IL202215A0 (en) 2010-06-16
JP2016006075A (ja) 2016-01-14
US9273134B2 (en) 2016-03-01
JP2010529127A (ja) 2010-08-26
WO2008153926A4 (en) 2009-05-22
CN101801407B (zh) 2013-12-18
CN103694351A (zh) 2014-04-02
EP2155238A2 (en) 2010-02-24
BRPI0812400A2 (pt) 2014-10-29
CN101801407A (zh) 2010-08-11
CA2687896A1 (en) 2008-12-18
JP6159760B2 (ja) 2017-07-05
EP2155238A4 (en) 2011-05-04
AU2008262384A1 (en) 2008-12-18
WO2008153926A2 (en) 2008-12-18
EP2155238B1 (en) 2016-04-06
WO2008153926A3 (en) 2009-03-19
AU2008262384B9 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
EA200901646A1 (ru) Ингибиторы рецепторных тирозинкиназ и их применение
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
EA200900403A1 (ru) Соединения, которые модулируют рецептор св2
ATE527253T1 (de) Pyrimidin-substituierte benzimidazolderivate als proteinkinasehemmer
NO20070908L (no) Sammensmeltede ringheterocykelkinasemodulatorer
EA200870410A1 (ru) Антагонисты киназы
EA201100523A1 (ru) Соединения сульфонила, которые селективно модулируют рецептор св2
EA201100306A1 (ru) Производные циклогексиламида и их применение в качестве антагонистов рецептора crf-1
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
MX354402B (es) Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
ATE512151T1 (de) Pyrrolotriazin-kinaseinhibitoren
EA201001331A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-kit И PDGFR
EA201200019A1 (ru) Соединения, которые селективно модулируют рецептор св2
EA201170227A1 (ru) Имидазолкарбоксамиды
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
BRPI0506679A (pt) métodos de tratar osteoartrite com antagonistas de il-6
BRPI0922224A2 (pt) composições de inibidores de proteína tirosina quiinase receptora.
EA200900783A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
ATE505191T1 (de) Ectoin zur behandlung von vascular leaks
CL2011000295A1 (es) Compuestos derivados de pirimidil-amino-benzamida; inhibidores de tirosin-quinasa; y su uso en el tratamiento de la hipertension pulmonar.
NO20093040L (no) Kinolinderivater som CRTH2 reseptorligander
EA201000494A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
ATE427927T1 (de) Phenylacetylenderivate mit affinitat zum mglur5- rezeptor